Human papillomaviruses (HPV are a necessary cause for cervical carcinoma, the third most common cancer among women worldwide. HPV DNA is detected in virtually every cervical carcinoma and about 50-60% of these are accounted for by the high risk HPV type 16. Efficient HPV replication conditions have not yet been mimicked in vitro thereby hampering the development of classical vaccines. However, when the major virion protein of the virus (L1) is over- expressed in eukaryotic cells, it self-assembles into virus-like particles (VLP). HPV VLP have become the leading strategy in vaccine trials for prevention of future HPV lesions by inducing neutralizing antibodies, but they are unlikely to have effects in the millions of women that are already infected and will not have any effect on existing cervical cancers that do no longer expression the L1 genes. They do, however, express the early gene products E6 and E7 that are selectively retained and expressed in cervical carcinoma and necessary for the transformed state of the cells. Therefore, incorporation of the E6 and E7 protein into chimeric VLP (cVLP) could confer a therapeutic potential to a VLP based vaccine. The tremendous potential of VLP has been shown in inducing T cell responses, in activating DC, in tumor preventive setting and, in preliminary ways also in tumor therapeutic settings and gene delivery. Based on these studies we now propose to explore the following new aims: 1) optimizing the use of HPV VLP as an antigen delivery system, 2) the use of HPV VLP as a tool for mapping human endogenously presented antigenic epitopes of HPV16 E6/E7 proteins, 3) the use of HPV VLP to explore the interaction of HPV with Langerhans cells, and 4) the use of HPV VLP as a gene delivery system. To achieve these aims the following methodology will be used: 1) delivery the of the HPV16 E6/E7 protein by different cVLP or different routes in order to avoid antibody activity against the cVLP that will neutralize repeated vaccination against the E6/E7 proteins, 2) in vitro immunization of human peripheral blood T cells with autologous DC loaded with cVLP expressing E6/E7 protein, 3) HPV VLP interaction and activation of human and mouse Langerhans cells, and 4) delivery of a new potential tumor suppressor gene or cytokine gene to cervical cancer cells and an antigen encoding gene or cytokine gene to dendritic cells. These combined aims will increase the potential and versatility of HPV VLP as therapeutic agents for HPV induced cervical cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA074397-07
Application #
6623517
Study Section
Special Emphasis Panel (ZRG1-SSS-4 (10))
Program Officer
Yovandich, Jason L
Project Start
1997-06-01
Project End
2003-08-31
Budget Start
2003-04-01
Budget End
2003-08-31
Support Year
7
Fiscal Year
2003
Total Cost
$296,370
Indirect Cost
Name
Loyola University Chicago
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153
Taylor, Julia R; Fernandez, Daniel J; Thornton, Shantaé M et al. (2018) Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation. Sci Rep 8:11642
Rodrigues, Luana L S; Morgado, Mariza G; Sahasrabuddhe, Vikrant V et al. (2018) Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors. Gynecol Oncol 151:102-110
Woodham, Andrew W; Cheloha, Ross W; Ling, Jingjing et al. (2018) Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res 6:870-880
Skeate, Joseph G; Da Silva, Diane M; Chavez-Juan, Elena et al. (2018) Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. PLoS One 13:e0191311
McCloskey, Jenny C; Kast, W Martin; Flexman, James P et al. (2017) Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. Papillomavirus Res 4:90-98
Skeate, Joseph G; Woodham, Andrew W; Einstein, Mark H et al. (2016) Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother 12:1418-29
Skeate, Joseph G; Porras, Tania B; Woodham, Andrew W et al. (2016) Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol 97:422-34
Da Silva, Diane M; Woodham, Andrew W; Naylor, Paul H et al. (2016) Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res 36:291-301
Weir, Genevieve M; Hrytsenko, Olga; Quinton, Tara et al. (2016) Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer 4:68
Woodham, Andrew W; Sanna, Adriana M; Taylor, Julia R et al. (2016) Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J 13:187

Showing the most recent 10 out of 80 publications